The  COURSE-AHC Study aims to define standard scales to evaluate the progressive course of AHC and possibly predict the changes in its severity with age. Such scales will be usable for larger studies of AHC to further refine the current knowledge of the course of AHC and of any other additional potential predictors of outcome over longer periods of time.
The study is led by Prof. Mohamad Mikati at the IAHCRC member Center of the Duke University in the USA, with the partcipation of the European IAHCRC member centers in Italy, Spain, France and UK. It has been concluded and it is currently in publication.

The MOME-AHC Project (Study of the Molecular Mechanisms in AHC) was intiated in 2013 by Prof. Fiorella Gurrieri and Dr. Danilo Tiziano at the IAHCRC member Center of the Università Cattolica in Rome, Italy. The first two phases were carried out in the next years, to develop a human cellular model of AHC and to identify signal transduction pathways disrupted by ATP1A3 mutations. The third ongoing phase, denominated TREAT-AHC Study, is aimed to develop a putative pharmacological correction of the cellular phenotype.
The MOME-AHC Project has always been funded by the Italian Association A.I.S.EA since its start and, more recently, also by the Spanish Association AESHA. 
Moreover, the TREAT-AHC Study presented at the 2019 edition of the Spanish Call "La Marató de TV3" by Prof. Danilo Tiziano and three IAHCRC clinical centers in Italy, Spain and France, has just been approved for funding. However, more funds will be needed to complete the preclinical phase, carried out in collaboration with the IAHCRC member Center led by Prof. Mohamad Mikati at the Duke University in the USA, and to bring candidate compounds to the treatment of AHC into the clinic.





last update 28 February 2021

IAHCRC - International Consortium for the Research on Alternating Hemiplegia of Childhood and other ATP1A3 related diseases